AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bingen, E.
Right arrow Articles by Deforche, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bingen, E.
Right arrow Articles by Deforche, D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, June 2000, p. 1453-1457, Vol. 44, No. 6
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Resistance to Macrolides in Streptococcus pyogenes in France in Pediatric Patients

Edouard Bingen,1,* Frederic Fitoussi,1 Catherine Doit,1 Robert Cohen,2 Asha Tanna,3 Robert George,3 Chawki Loukil,1 Naima Brahimi,1 Isabelle Le Thomas,1 and Dominique Deforche1

Service de Microbiologie, Hôpital Robert Debré, 75019 Paris,1 and Service de Microbiologie, Centre Hospitalier de Créteil, 94010 Créteil,2 France, and Central Public Health Laboratory, London, United Kingdom3

Received 2 September 1999/Returned for modification 26 December 1999/Accepted 3 March 2000

A total of 1,500 recent throat isolates of Streptococcus pyogenes collected between 1996 and 1999 from children throughout France were tested for their susceptibility to erythromycin, azithromycin, josamycin, clindamycin, and streptogramin B. The erythromycin-resistant isolates were further studied for their genetic mechanism of resistance, by means of PCR. The clonality of these strains was also investigated by means of serotyping and ribotyping. In all, 6.2% of the strains were erythromycin resistant, and 3.4 and 2.8% expressed the constitutive MLSB and M resistance phenotypes and harbored the ermB and mefA genes, respectively; ermTR was recovered from one isolate which also harbored the ermB gene. Ten serotypes and 8 ribotypes were identified, but we identified 17 strains by combining serotyping with ribotyping. Among the eight ribotypes, the mefA gene was recovered from six clusters, one being predominant, while the ermB gene was recovered from four clusters, of which two were predominant.


* Corresponding author. Mailing address: Service de Microbiologie, Hôpital R. Debré, 48 Bd Sérurier, 75019 Paris, France. Phone: 33 (1) 40 03 23 40. Fax: 33 (1) 40 03 24 50. E-mail: edouard.bingen{at}rdb.ap-hop-paris.fr.


Antimicrobial Agents and Chemotherapy, June 2000, p. 1453-1457, Vol. 44, No. 6
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2000 by the American Society for Microbiology. All rights reserved.